Advertisement

Topics

SIRAKOSS Ltd Company Profile

06:34 EDT 23rd March 2019 | BioPortfolio

SIRAKOSS is developing nanosynthetic graft substitutes to facilitate complete bone repair and transform patient healing. The SIRAKOSS bone graft substitutes utilise advanced and proprietary understanding of nanostructures and nanochemistry to catalyze faster bone regeneration coupled with total graft resorption. SIRAKOSS was spun out of the University of Aberdeen in 2011 based on the research of Professor Iain Gibson and is supported through financing from Epidarex Capital and Scottish Investment Bank, the investment arm of Scottish Enterprise together with grant funding from Innovate UK. For more information visit www.sirakoss.com.


News Articles [5 Associated News Articles listed on BioPortfolio]

EU approves Sirakoss' nanosynthetic bone graft substitute

European regulators have given Sirakoss CE mark approval for Osteo3, a nanosynthetic bone graft substitute with a surface che -More- 

Sirakoss’Osteo3 synthetic bone graft substitute receives CE mark

Osteo3 is a nanosynthetic bone graft substitute designed to improve patient healing and providing surgeons with a more advanced solution for repairing bone fractures. Synthetic bone grafts are The po...

SIRAKOSS Receives CE Mark for Osteo3 Synthetic Bone Graft Substitute

Represents New Hope for Repairing Challenging Bone Fractures SIRAKOSS Ltd, a developer of unique synthetic bone graft substitutes, announced today it has been granted CE Mark ...

Bumps In The Road As US FDA Tries To Catch Up From Shutdown

It is not anticipated that the recently ended record US government shutdown will have a long-term impact on US FDA...   

2018 Slow For Advertising Enforcement – But Don’t Get Complacent

US FDA issued only one warning letter directly related to medical device advertising or promotion in 2018. But that doesn’t...   

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

SIRAKOSS Ltd

SIRAKOSS is developing nanosynthetic graft substitutes to facilitate complete bone repair and transform patient healing. The SIRAKOSS bone graft substitutes utilise advanced and p...

More Information about "SIRAKOSS Ltd" on BioPortfolio

We have published hundreds of SIRAKOSS Ltd news stories on BioPortfolio along with dozens of SIRAKOSS Ltd Clinical Trials and PubMed Articles about SIRAKOSS Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SIRAKOSS Ltd Companies in our database. You can also find out about relevant SIRAKOSS Ltd Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...

Complementary and Alternative Medicine
Alternative medicine are whole medical systems that did not fit with conventional medicine as they have completely different philosophies and ideas on the causes of disease, methods of diagnosis and approaches to treatment. Although often overlapping, co...


Corporate Database Quicklinks



Searches Linking to this Company Record